Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Current Leases (2021 - 2026)

Atea Pharmaceuticals' Current Leases history spans 6 years, with the latest figure at $634000.0 for Q1 2026.

  • Quarterly Current Leases fell 21.82% to $634000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $634000.0 through Mar 2026, down 21.82% year-over-year, with the annual reading at $843000.0 for FY2025, 5.37% up from the prior year.
  • Current Leases came in at $634000.0 for Q1 2026, down from $843000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $843000.0 in Q4 2025 to a low of $113000.0 in Q1 2022.
  • The 5-year median for Current Leases is $760000.0 (2023), against an average of $725588.2.
  • Year-over-year, Current Leases surged 546.02% in 2023 and then fell 21.82% in 2026.
  • Atea Pharmaceuticals' Current Leases stood at $721000.0 in 2022, then grew by 5.41% to $760000.0 in 2023, then grew by 5.26% to $800000.0 in 2024, then rose by 5.38% to $843000.0 in 2025, then dropped by 24.79% to $634000.0 in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Current Leases are $634000.0 (Q1 2026), $843000.0 (Q4 2025), and $832000.0 (Q3 2025).